|
US6846839B1
(en)
|
1995-06-07 |
2005-01-25 |
Sugen, Inc. |
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
AR012634A1
(es)
*
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
WO2000056338A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Parker Hughes Institute |
Quinazoline formulations and therapeutic use thereof
|
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
|
ATE272406T1
(de)
*
|
1999-04-09 |
2004-08-15 |
Max Planck Gesellschaft |
Prognose von ptp lar vermittelten krankheiten
|
|
KR20020029419A
(ko)
*
|
1999-07-07 |
2002-04-18 |
다비드 에 질레스 |
퀴나졸린 유도체
|
|
GB9925127D0
(en)
*
|
1999-10-22 |
1999-12-22 |
Pharmacia & Upjohn Spa |
Oral formulations for anti-tumor compounds
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
EP1259234B9
(en)
*
|
1999-12-30 |
2007-02-14 |
Sugen, Inc. |
3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
|
|
US6573293B2
(en)
|
2000-02-15 |
2003-06-03 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
WO2001066099A2
(en)
|
2000-03-06 |
2001-09-13 |
Astrazeneca Ab |
Use of quinazoline derivatives as angiogenesis inhibitors
|
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
|
US6706709B2
(en)
|
2000-06-02 |
2004-03-16 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
|
ATE413394T1
(de)
|
2000-06-24 |
2008-11-15 |
Astrazeneca Ab |
Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten
|
|
AU2002216758A1
(en)
*
|
2000-07-03 |
2002-01-14 |
Astrazeneca Ab |
Quinazolines with therapeutic use
|
|
DE60109295T2
(de)
*
|
2000-07-24 |
2006-04-13 |
Sugen, Inc., South San Francisco |
Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
|
|
US20020036154A1
(en)
*
|
2000-08-10 |
2002-03-28 |
Ramaswamy Murari |
Solid pharmaceutical dosage formulation of hydrophobic drugs
|
|
US20050158271A1
(en)
*
|
2000-10-11 |
2005-07-21 |
Lee Sang C. |
Pharmaceutical applications of hydrotropic polymer micelles
|
|
AU2002214583A1
(en)
*
|
2000-10-11 |
2002-04-22 |
Purdue Research Foundation |
Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
WO2002069936A2
(en)
*
|
2001-03-02 |
2002-09-12 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical composition of ibuprofen
|
|
US6912582B2
(en)
|
2001-03-30 |
2005-06-28 |
Microsoft Corporation |
Service routing and web integration in a distributed multi-site user authentication system
|
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
|
US6720002B2
(en)
*
|
2001-07-20 |
2004-04-13 |
R.P. Scherer Technologies, Inc. |
Antihistamine formulations for soft capsule dosage forms
|
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
|
BR0214357A
(pt)
*
|
2001-11-21 |
2004-09-14 |
Sugen Inc |
Formulações farmacêuticas compreendendo derivados de indolinona
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
|
PL371587A1
(en)
*
|
2002-01-17 |
2005-06-27 |
Neurogen Corporation |
Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
|
|
AU2003216282A1
(en)
*
|
2002-02-15 |
2003-09-09 |
Pharmacia And Upjohn Company Llc |
Process for preparing indolinone derivatives
|
|
KR101002374B1
(ko)
*
|
2002-02-26 |
2010-12-17 |
아스트라제네카 아베 |
수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
|
|
JP4628678B2
(ja)
*
|
2002-03-29 |
2011-02-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用
|
|
US8299108B2
(en)
*
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
KR20040106391A
(ko)
|
2002-04-26 |
2004-12-17 |
니뽄 신야쿠 가부시키가이샤 |
퀴나졸린 유도체 및 의약
|
|
WO2004055004A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
ITRM20030074A1
(it)
*
|
2003-02-21 |
2004-08-22 |
Pharmacia Italia Spa |
Formulazioni semisolide a rilascio immediato intese
|
|
US7893096B2
(en)
*
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
|
CA2522522A1
(en)
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Quinazoline compounds
|
|
AU2004229163A1
(en)
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
(6-(phenoxy)-pyrido`3,4-d! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
|
US7569577B2
(en)
|
2003-09-16 |
2009-08-04 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
CA2542653A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Chiron Corporation |
Substituted benzazoles and use thereof as inhibitors of raf kinase
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7491263B2
(en)
|
2004-04-05 |
2009-02-17 |
Technology Innovation, Llc |
Storage assembly
|
|
ME01267B
(me)
|
2004-05-06 |
2013-06-20 |
Warner Lambert Co |
4-fenilaminokinazolin-6-ilamidi
|
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
|
EP1765810B1
(en)
*
|
2004-06-08 |
2016-08-17 |
Families of Spinal Muscular Atrophy |
2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
|
|
MX2007005408A
(es)
*
|
2004-11-09 |
2007-05-16 |
Hoffmann La Roche |
Compuestos de aminoquinazolinas.
|
|
CN101124228B
(zh)
|
2004-12-14 |
2011-06-15 |
阿斯利康(瑞典)有限公司 |
用作抗肿瘤药物的吡唑并嘧啶化合物
|
|
MX2007011250A
(es)
*
|
2005-03-21 |
2007-11-14 |
Ivax Pharmaceuticals Sro |
Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
SI1971338T1
(sl)
*
|
2005-12-22 |
2011-06-30 |
Astrazeneca Ab |
Kombinacija ZD6474 in pemetrekseda
|
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
|
MX2008010953A
(es)
*
|
2006-02-28 |
2008-09-08 |
Amgen Inc |
Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
|
|
US7985755B2
(en)
*
|
2006-08-01 |
2011-07-26 |
Families Of Spinal Muscular Atrophy |
2,4-diaminoquinazolines for spinal muscular atrophy
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
EP2200613B1
(en)
|
2007-09-21 |
2018-09-05 |
The Johns Hopkins University |
Phenazine derivatives and uses thereof
|
|
RS52573B
(sr)
|
2008-02-07 |
2013-04-30 |
Boehringer Ingelheim International Gmbh |
Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
|
|
WO2009114365A2
(en)
*
|
2008-03-13 |
2009-09-17 |
Mallinckrodt Inc. |
Multi-function, foot-activated controller for imaging system
|
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
|
JP5359333B2
(ja)
*
|
2009-02-05 |
2013-12-04 |
ゼリア新薬工業株式会社 |
コロソリン酸含有水性液剤
|
|
RU2529019C2
(ru)
*
|
2009-02-27 |
2014-09-27 |
Эмбит Байосайенсиз Корпорейшн |
Модулирующие jak киназу хиназолиновые производные и способы их применения
|
|
PE20121153A1
(es)
|
2009-09-03 |
2012-08-27 |
Bristol Myers Squibb Co |
Quinazolinas como inhibidores de los canales ionicos de potasio
|
|
EP2498753B1
(en)
*
|
2009-11-10 |
2019-03-06 |
Celgene Corporation |
Nanosuspension of a poorly soluble drug made by microfluidization process
|
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
|
CN102716103B
(zh)
*
|
2012-07-02 |
2013-12-18 |
西安力邦制药有限公司 |
2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
CN103837615B
(zh)
*
|
2014-02-15 |
2015-05-20 |
青岛农业大学 |
一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法
|
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
US20160361322A1
(en)
|
2015-06-15 |
2016-12-15 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
|
CA3037456A1
(en)
|
2016-09-19 |
2018-03-22 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
US20180147215A1
(en)
|
2016-11-28 |
2018-05-31 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
|
IL270224B1
(en)
|
2017-05-02 |
2024-04-01 |
Novartis Ag |
Combination therapy employing trametinib and a defined raf inhibitor
|
|
AU2019308326B2
(en)
|
2018-07-20 |
2025-07-31 |
Lipocine Inc. |
Liver disease
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
EP4138783A4
(en)
*
|
2020-04-22 |
2024-04-10 |
Scienture, Inc. |
LONG-ACTING BUPIVACAIN MICROSPHERE FORMULATIONS
|
|
CN113398067B
(zh)
*
|
2021-07-19 |
2022-08-16 |
宁波三生生物科技股份有限公司 |
一种四烯雌酮注射液及其制备方法和应用
|